

MATTHEW VOGEL

Brown University • 121 South Main Street • Providence, RI 02903
matthew_vogel@brown.edu • (617) 571-0502

Updated: September 3, 2026

ACADEMIC APPOINTMENTS

- | | |
|--------------|--|
| 2026–present | Professor of the Practice
Department of Health Services, Policy, and Practice
School of Public Health
Brown University

Watson School of International and Public Affairs
Brown University |
| 2024–present | Research Fellow
Mossavar-Rahmani Center for Business and Government
Harvard Kennedy School |
| 2023–2026 | Visiting Scientist
Department of Medical Oncology
Dana-Farber Cancer Institute |
| 2022–2024 | Senior Fellow
Mossavar-Rahmani Center for Business and Government
Harvard Kennedy School |

EDUCATION

- | | |
|------|---|
| 2008 | M.B.A., Finance and Accounting
The Wharton School, University of Pennsylvania |
| 2000 | B.Sc., International Politics
Edmund A. Walsh School of Foreign Service, Georgetown University |

AWARDS

- | | |
|------|--|
| 2025 | Publication-of-the-Year Award
AcademyHealth |
|------|--|

GRANTS

- 2026–2027 Co-Investigator (PI: Amitabh Chandra, Harvard University), grant from Harvard Innovation Labs to study the implications of China’s emerging biopharma industry for U.S. policy (\$85,750)
- 2026–2028 Co-Investigator (PI: Olivier Wouters, Brown University), grant from Arnold Ventures to estimate the research and development investments required to bring a new medicine to market (\$399,981)
- 2025–2027 Co-Investigator (PI: Olivier Wouters, Brown University), grant from Arnold Ventures to study the impact of the Trump Administration’s Most Favored Nation drug pricing plan (\$397,750)
- 2025–2026 Co-Investigator (PI: Olivier Wouters, Brown University), grant from the National Institute on Aging to study market failures in drug development for Alzheimer’s disease (\$199,311)

PEER-REVIEWED PUBLICATIONS

Vogel M, Cowan Z, Chandra A. Lessons from Drug Revenue Life Cycles: Distributions Across Modalities and Therapeutic Areas: Lessons for Innovators and Investors. *Nature Biotechnology*. 2026 August 18.

Vogel M, Colombo R, Tarantino P. Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates. *J Clin Oncol*. 2025 Nov;43(31):3339-3344.

Vogel M, Feldman WB, Cowan Z, Rome BN, Chandra A, Kesselheim AS, Wouters OJ. Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare. *JAMA Health Forum*. 2025 Oct 3;6(10):e254720.

Wouters OJ, **Vogel M**, Feldman WB, Beall RF, Kesselheim AS, Tu SS. Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US. *JAMA*. 2024 Dec 24;332(24):2101-2108.

** 2025 AcademyHealth Publication-of-the-Year Award

Vogel M, Tellier A, Conti RM. Predicting the next round of drugs for Medicare price negotiation. *Sci Transl Med*. 2024 Dec 4;16(776):eadq5711.

Vogel M, Rome BN, Kesselheim AS, Feldman WB. Medicare Negotiation's Drug Reformulation Problem. *Ann Intern Med*. 2024 Jun;177(6):817-819.

Vogel M, Kakani P, Chandra A, Conti RM. Medicare price negotiation and pharmaceutical innovation following the Inflation Reduction Act. *Nat Biotechnol*. 2024 Mar;42(3):406-412.

Vogel M, Zhao O, Feldman WB, Chandra A, Kesselheim AS, Rome BN. Cost of Exempting Sole Orphan Drugs From Medicare Negotiation. *JAMA Intern Med*. 2024 Jan 1;184(1):63-69.

Vogel M, Kesselheim AS, Feldman WB, Rome BN. Will Medicare Price Negotiation Delay Cancer-Drug Launches? *N Engl J Med*. 2023 Oct 26;389(17):1546-1548.

In Press

Vogel M, Wouters OJ. Policy and Design Considerations for Most-Favored-Nation Drug Pricing. *JAMA Intern Med*. 2026 Dec;186(12).

Under Peer Review

Vogel M, Yaeger R, Wouters OJ. Clinical Trial Prediction Markets – Information at What Cost? *The New England Journal of Medicine*.

Vogel M, Liu S, Sharma V, Wouters OJ. Medicare Spending and Most-Favored-Nation Pricing Models. *Health Affairs Scholar*

Wouters OJ, Guanqiao Li, Shadlen K, Abrahams C, Liao I, Chen C, **Vogel M**, Pu Y, Hediger S, Mercadante E, Vokinger K. Trends in Pharmaceutical Innovation in China, Europe, and the United States, 2010-2025. *JAMA Internal Medicine*.

Stewart D, Kurzrock R, **Vogel M**, Subbiah V, Gotfrit J, Sehdev S, Jiang D, Cole K, Batist G, Liu G, Kucharczyk M, Navani V, Chang TY, Ramsay T. Overall Survival and the Risks of False Negatives: Why Progression-Free Survival Matters. *British Journal of Cancer*.

ADDITIONAL PUBLICATIONS

Vogel M, Rangaraj S, Wouters OJ. The Trump Administration's Deals with Pharma: Policy Progress or Political Theater? *Health Affairs Forefront*, Jul 2026.

Stewart DJ, Subbiah V, **Vogel M**, Ramsay T, Kurzrock R. Factors That Can Make Overall Survival Unreliable as a Clinical Trial Outcome. *Lancet Oncol*. 2026 Feb;27(2):e66.

Vogel M, Yaeger R, Stewart DJ, Subbiah V, David FS. Surrogate end points in oncology: aligning drug development incentives and patient needs. *Nat Rev Clin Oncol*. 2025 Aug;22(8):617-618.

Vogel M, Conti RM. Post-Approval Innovation for Oncology Drugs. *Health Affairs*. May 2025, 44(5):639-639.

Vogel M, Chandra A, Conti RM. Biopharma Venture Capital and the Inflation Reduction Act, *Health Affairs Forefront*, Mar 2024.

REPORTS

Vogel M. Hitting the Ground Running: A Guide to Presidential Transitions. 2008. Obama-Biden Presidential Transition. 93 p.

Vogel M. Appointing the Presidency: A Practical Guide to Personnel for the Transition and Beyond. 2000. Gore-Lieberman Presidential Transition. 106 p.

PROFESSIONAL AND GOVERNMENT APPOINTMENTS

2017–2022	D.E. Shaw Group Senior Vice President - Served as co-head of the Chief Operating Officer business unit for a \$60 billion quantitative hedge fund. - Responsible for corporate strategy, business planning, and external communications.	New York, NY
2016–2017 2013–2016	Office of the U.S. Trade Representative Acting Deputy United States Trade Representative Chief of Staff - Appointed by President Obama to senior leadership of the 300-person cabinet agency responsible for executing the president’s trade agenda. - Led U.S. government engagement with NAFTA countries and Latin America on trade issues. - Managed offices handling interagency coordination, economic analysis, media affairs, congressional relations, and stakeholder engagement. - Successful initiatives included passage of the Bipartisan Congressional Trade Priorities and Accountability Act of 2015, the Trade Facilitation and Enforcement Act of 2015, the Trade Preferences Extension Act of 2015, and the Trade Adjustment Assistance Act of 2015.	Washington, DC
2011–2013	The White House – National Security Council Special Assistant to the President for Economic Policy Led U.S. government preparation for G-8 and G-20 leaders’ summits, organized the 2012 Camp David G-8 summit, advised and accompanied President Obama on travel related to international economic diplomacy.	Washington, DC

2010–2011	The White House – National Economic Council Special Assistant to the President and Chief of Staff Served as staff director for the White House office responsible for the development of U.S. economic policy in key areas, including health care, regulatory affairs, tax, and budget.	Washington, DC
2009–2010	Associate White House Communications Director for Economics Developed media strategies and served as White House spokesman on economic policy.	
2008–2009	Morgan Stanley Associate, Mergers and Acquisitions Department Provided strategic and financial advice to publicly traded and private companies regarding mergers and acquisitions, licensing, equity and debt financing, and shareholder activism.	New York, NY
2005–2006 2004–2005	Office of U.S. Representative Martin Meehan Chief of Staff Communications Director - Served as staff director for a Member of the U.S. House of Representatives - Supervised 15 employees and led all aspects of policy development, legislative strategy, and public communications.	Washington, DC
2001–2003	SG Cowen Securities Biotechnology Equity Research Assistant - Supported senior analysts covering 32 biotechnology companies by preparing research notes and reports and engaging with management teams, institutional investors, and key opinion leaders. - Built and maintained financial and epidemiology-based forecast models to support company valuations and investment research.	Boston, MA

PROFESSIONAL MEMBERSHIPS

2018–	Life Member Council on Foreign Relations Elected as a life member of the selective, nonpartisan organization that convenes leaders, experts, and policymakers to address global issues.
2025–	Member American Society of Clinical Oncology

SERVICE

Public Policy

- 2024 Economic policy advisor, Biden-Harris Presidential Transition
- Authored transition policy memos for the Office of the U.S. Trade Representative and for international economic diplomacy.

Scientific Research

- 2021– Research director, Amy Sobel Foundation
- Oversee grantmaking and scientific communications for a philanthropy focused on translational research for inflammatory bowel disease (IBD) and IBD-associated cancer.

Peer Reviewer

Drug Discovery Today
Health Affairs Scholar
JAMA Network Open
PLOS Global Public Health
Value in Health